Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IPH4502 · 1 trial · 1 indication
To evaluate the incidence of AEs, SAEs, TEAEs, and DLTs.
| Arm | Type | Description |
|---|---|---|
| IPH4502 Monotherapy | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| IPH4502 | DRUG | Part 1 (dose escalation) and Part 2 (dose optimization) |
Main Inclusion Criteria: * Histologically confirmed, unresectable, locally advanced or metastatic solid tumors that are known to express Nectin-4 * Prior systemic treatment for locally advanced or metastatic disease, yet no therapy with demonstrated clinical benefit for the tumor type is available....
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
IPH4502 is an investigational small molecule antibody-drug conjugate (ADC) being developed for the treatment of advanced or metastatic solid tumors. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
IPH4502 targets Nectin-4, a cell surface protein commonly expressed in various solid tumors. As an antibody-drug conjugate, it is designed to deliver a cytotoxic payload specifically to Nectin-4-expressing cancer cells, potentially reducing damage to healthy tissues.
IPH4502 is being developed by Innate Pharma S.A., a biopharmaceutical company listed on the stock exchange under the ticker symbol IPHA. The company is conducting clinical trials to evaluate the safety and tolerability of this investigational drug.
IPH4502 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or any other regulatory agency. The ongoing Phase 1 trial is assessing its safety and tolerability in patients with advanced solid tumors.
IPH4502 is being evaluated in a Phase 1 clinical trial with the identifier NCT06781983, titled 'Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors.' The trial is active but not recruiting, with an estimated enrollment of 145 participants across the United States and France.
IPH4502 is a Nectin-4-targeting antibody-drug conjugate (ADC). While it specifically targets Nectin-4, it is a distinct investigational drug candidate developed by Innate Pharma. It is not the same as other Nectin-4 ADCs, such as enfortumab vedotin, which is a different product.